$ELV · Elevance Health, Inc.
Elevance Health reported third quarter 2026 operating revenue of $50.4 billion, up 0.7% from the prior year. Diluted earnings per share were $6.27, while adjusted diluted EPS was $6.99, which included a net non-operating benefit of $1.85 per share. The company raised its full-year 2026 guidance, now expecting diluted EPS of at least $22.00 and adjusted diluted EPS of at least $29.00, along with operating cash flow of at least $6.5 billion. Management also stated confidence in delivering at least 12% growth in adjusted diluted EPS in 2027 from a higher earnings baseline of at least $26.75.
The Health Benefits segment posted operating revenue of $43.4 billion, up 3%, but operating gain declined to $0.4 billion due to targeted investments. Carelon revenue rose 5% to $19.3 billion, with operating gain up 17% to $0.9 billion, driven by risk-based solutions and specialty pharmacy profitability. Total medical membership fell by 487,000 year over year to approximately 44.9 million, reflecting lower Medicaid, Medicare Advantage, and Employer Group risk enrollment. The benefit expense ratio improved 70 basis points to 90.6%. The company also declared a fourth quarter dividend of $1.72 per share, payable on December 18, 2026.